Shanghai Haohai Biological Technology (HKG:6826) booked 251 million yuan in attributable profit for 2025, down 40% from 420.4 million yuan in 2024, according to a Hong Kong bourse filing Friday.
Shares of the firm fell over 1% in late morning trade Monday.
Earnings per share was 1.08 yuan, compared with 1.80 yuan in the prior year.
Revenue fell 8.7% year on year to 2.45 billion yuan, figures showed.
The company also proposed a dividend of 0.6 yuan per share.